Galcanezumab: CGRP Antibody for Migraine Prevention
Galcanezumab is a monoclonal antibody used for migraine prevention. It targets the CGRP molecule, reducing the frequency and severity of migraine attacks in adults.
Things worth knowing about "Galcanezumab"
Galcanezumab is a monoclonal antibody used for migraine prevention. It targets the CGRP molecule, reducing the frequency and severity of migraine attacks in adults.
What is Galcanezumab?
Galcanezumab (brand name: Emgality) is a monoclonal antibody approved for the preventive treatment (prophylaxis) of migraine in adults. It belongs to the drug class of CGRP inhibitors and has been authorized by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Galcanezumab is also approved for the treatment of episodic cluster headache.
Indications
Galcanezumab is indicated for:
- Prophylaxis of episodic migraine (fewer than 15 migraine days per month)
- Prophylaxis of chronic migraine (15 or more headache days per month, at least 8 of which have migraine features)
- Episodic cluster headache (treatment of active cluster periods)
Mechanism of Action
Galcanezumab works by binding with high affinity and specificity to CGRP (Calcitonin Gene-Related Peptide), a neuropeptide that is released in elevated amounts during a migraine attack. CGRP promotes the dilation of blood vessels in the brain and plays a key role in transmitting pain signals.
By directly neutralizing the CGRP molecule before it can bind to its receptor, galcanezumab effectively prevents the cascade of events that leads to a migraine attack. This results in a significant reduction in the frequency and intensity of migraines without substantially affecting normal brain function.
Dosage and Administration
Galcanezumab is administered as a subcutaneous injection (under the skin), typically once a month. After proper medical training, patients can self-administer the medication using a prefilled pen or prefilled syringe.
- Migraine prevention: Loading dose of 240 mg (two injections of 120 mg each), followed by 120 mg once monthly
- Cluster headache: 300 mg (three injections of 100 mg each) at the start of a cluster period
Treatment duration should be reviewed regularly by a physician, typically after no more than 12 months of continuous use.
Side Effects
Galcanezumab is generally well tolerated. The most commonly reported side effects include:
- Injection site reactions (pain, redness, itching)
- Skin rash or itching (pruritus)
- Dizziness
- Constipation
Serious side effects such as allergic or hypersensitivity reactions are rare but possible. Patients should contact their healthcare provider immediately if they notice signs of a severe allergic reaction.
Contraindications and Interactions
Galcanezumab should not be used in patients with a known hypersensitivity to the active substance or any of its excipients. As a biological antibody, galcanezumab carries a lower risk of classical drug-drug interactions compared to small-molecule medications. However, its safety during pregnancy and breastfeeding has not been sufficiently established, and use should only occur after careful medical evaluation.
Treatment Context
Galcanezumab represents a new generation of migraine preventives known as CGRP monoclonal antibodies. It is typically considered when conventional prophylactics (e.g., beta-blockers, topiramate, amitriptyline) have been ineffective or poorly tolerated. Landmark clinical trials (EVOLVE-1, EVOLVE-2, REGAIN) demonstrated that galcanezumab significantly reduces monthly migraine days and meaningfully improves the quality of life of affected patients.
References
- European Medicines Agency (EMA): Emgality (galcanezumab) - Summary of Product Characteristics. www.ema.europa.eu
- Stauffer VL et al. - Evaluation of Galcanezumab for the Prevention of Episodic Migraine. JAMA Neurology, 2018.
- Goadsby PJ et al. - A Controlled Trial of Erenumab for Episodic Migraine. New England Journal of Medicine, 2017 (contextual CGRP class reference).
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryBone augmentation
AC joint osteoarthritis
Corrective osteotomy
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Galcanezumab